OBJECTIVES:  Chemotherapy with docetaxel was the first therapy approved for the treatment of metastatic Castrate-Resistant Prostate Cancer (mCRPC) while others came along rather recently. With all the treatment options available now, current treatment strategies to appropriately sequence these agents are not known. This study aims to describe mCRPC current treatment paradigms, with specific attention to docetaxel, in Scotland. METHODS: : A retrospective chart review was conducted. A panel of Scottish physicians was contacted to identify patients diagnosed with mCRPC between 2008 and 2013. Collected data included demographics, disease history, sequencing of therapies (type, duration and time-to-event), reason for switch or discontinuation, drug-related serious adverse events and hospitalisations. Descriptive analyses were performed. Time-to-event was analysed using the Kaplan-Meier method. RESULTS: : 12 physicians in Scotland completed the survey and 34 patients were included in the analysis. Mean age at mCRPC diagnosis was 62 years (range 56-69 years). The mean duration between mCRPC diagnosis and the date of last contact was 1.20 years. Postcastration, most patients (19/34, 56%), received docetaxel as first-line. The second most frequent first-line was bicalutamide (14/34, 41%), alone (9/14, 64%) or in combination with LHRHa. Abiraterone was frequently prescribed as next (second or third) line of therapy after docetaxel (6/21, 29%). The median time to switch was 105 days (range 20-235 days) and did not differ between patients with docetaxel versus other as first-line (p = 0.17). Most patients switched after radiographic progression or PSA rise. Serious adverse events and hospitalisations were rarely reported. CONCLUSIONS: These findings provide insights into the treatment pathway of mCRPC patients in Scotland. Chemotherapy with docetaxel and hormonal agents appear to be the most utilised therapies. Switch from first-line treatment occurred in approximately 3.5 months and was facilitated by radiographic progression or PSA rise. A larger retrospective chart review is needed to confirm these results.